Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40

Glioblastomas are generally resistant to treatment with immune checkpoint inhibitors. Here the authors show that IL6 blockade, in combination with a CD40 agonist, overcomes macrophage-mediated immunosuppression and sensitizes glioblastoma to immune checkpoint blockade in preclinical models.

Guardado en:

Detalles Bibliográficos
Autores principales:	Fan Yang, Zhenqiang He, Hao Duan, Duo Zhang, Juehui Li, Huijuan Yang, Jay F. Dorsey, Wei Zou, S. Ali Nabavizadeh, Stephen J. Bagley, Kalil Abdullah, Steven Brem, Lin Zhang, Xiaowei Xu, Katelyn T. Byrne, Robert H. Vonderheide, Yanqing Gong, Yi Fan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/b5c127f1aaa240298e7d6cf386dcde4f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b5c127f1aaa240298e7d6cf386dcde4f
record_format	dspace
spelling	oai:doaj.org-article:b5c127f1aaa240298e7d6cf386dcde4f2021-12-02T17:47:02ZSynergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD4010.1038/s41467-021-23832-32041-1723https://doaj.org/article/b5c127f1aaa240298e7d6cf386dcde4f2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-23832-3https://doaj.org/toc/2041-1723Glioblastomas are generally resistant to treatment with immune checkpoint inhibitors. Here the authors show that IL6 blockade, in combination with a CD40 agonist, overcomes macrophage-mediated immunosuppression and sensitizes glioblastoma to immune checkpoint blockade in preclinical models.Fan YangZhenqiang HeHao DuanDuo ZhangJuehui LiHuijuan YangJay F. DorseyWei ZouS. Ali NabavizadehStephen J. BagleyKalil AbdullahSteven BremLin ZhangXiaowei XuKatelyn T. ByrneRobert H. VonderheideYanqing GongYi FanNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Fan Yang Zhenqiang He Hao Duan Duo Zhang Juehui Li Huijuan Yang Jay F. Dorsey Wei Zou S. Ali Nabavizadeh Stephen J. Bagley Kalil Abdullah Steven Brem Lin Zhang Xiaowei Xu Katelyn T. Byrne Robert H. Vonderheide Yanqing Gong Yi Fan Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
description	Glioblastomas are generally resistant to treatment with immune checkpoint inhibitors. Here the authors show that IL6 blockade, in combination with a CD40 agonist, overcomes macrophage-mediated immunosuppression and sensitizes glioblastoma to immune checkpoint blockade in preclinical models.
format	article
author	Fan Yang Zhenqiang He Hao Duan Duo Zhang Juehui Li Huijuan Yang Jay F. Dorsey Wei Zou S. Ali Nabavizadeh Stephen J. Bagley Kalil Abdullah Steven Brem Lin Zhang Xiaowei Xu Katelyn T. Byrne Robert H. Vonderheide Yanqing Gong Yi Fan
author_facet	Fan Yang Zhenqiang He Hao Duan Duo Zhang Juehui Li Huijuan Yang Jay F. Dorsey Wei Zou S. Ali Nabavizadeh Stephen J. Bagley Kalil Abdullah Steven Brem Lin Zhang Xiaowei Xu Katelyn T. Byrne Robert H. Vonderheide Yanqing Gong Yi Fan
author_sort	Fan Yang
title	Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
title_short	Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
title_full	Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
title_fullStr	Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
title_full_unstemmed	Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
title_sort	synergistic immunotherapy of glioblastoma by dual targeting of il-6 and cd40
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b5c127f1aaa240298e7d6cf386dcde4f
work_keys_str_mv	AT fanyang synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT zhenqianghe synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT haoduan synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT duozhang synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT juehuili synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT huijuanyang synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT jayfdorsey synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT weizou synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT salinabavizadeh synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT stephenjbagley synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT kalilabdullah synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT stevenbrem synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT linzhang synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT xiaoweixu synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT katelyntbyrne synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT roberthvonderheide synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT yanqinggong synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40 AT yifan synergisticimmunotherapyofglioblastomabydualtargetingofil6andcd40
_version_	1718379550497308672

Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40

Ejemplares similares